INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORA Patent applications |
Patent application number | Title | Published |
20130191934 | TREATMENT OF SYMPTOMS ASSOCIATED WITH MENOPAUSE - A method for treating symptoms associated with a dramatic reduction in reproductive hormone levels is provided, particularly in menopausal women and breast cancer survivors undergoing aromatase inhibitor therapy. The method comprises administered to a subject an inhibitor of orexin activity in an amount sufficient to reduce or decrease onset, progression, severity, frequency, duration or probability of one or more such symptoms. A method of detecting compounds having activity for relieving menopausal symptoms is also provided. | 07-25-2013 |
20130189282 | METHODS FOR ISOLATING AND USING A SUBSET OF CD8 T-CELLS THAT ARE RESISTANT TO CYCLOSPORIN - Utilizing a novel T cell culture system based on allogeneic epithelial antigen presenting cells (semi-professional APC), a cyclosporin-resistant CD8 T cell clone with minimal cytolytic capability was isolated. Derivation of the novel alloantigen-specific CD8 T cell clones involved previous priming with an allogeneic skin graft, implying expansion of this T cell subset during transplant rejection. Characterization and comparison of the cyclosporin and rapamycin-resistant CD 8 T cell clone with typical cyclosporin-sensitive CD 8 T cells suggests that it is a member of a CD8 T cell subset with a unique cell surface phenotype and novel TCR activation pathways, and that these unique CD8 T cell clones reflect the immunobiology of chronic rejection within the non-hematopoetic microenvironments of solid organs and vascular walls. These cells express the aryl-hydrocarbon receptor. T-cells of this type are referred to herein as CD8bm12-1 T-cells. | 07-25-2013 |
20130123171 | AMIDE-BASED INSULIN PRODRUGS - Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 05-16-2013 |
20120195978 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER - Administration of compositions comprising cell-permeable caPCNA-derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins. | 08-02-2012 |
20110143386 | METHOD FOR THE ANALYSIS OF O-LINKED OLIOSACHARIDES - A method of analyzing O-linked oligosaccharides in a sample is disclosed. The method comprises the steps of digesting a glycoprotein with a proteolytic enzyme, performing solid-phase permethylation of the oligosaccharide, then analyzing the permethylated and non-reduced O-linked oligosaccharides using MALDI-TOF mass spectrometry. | 06-16-2011 |
20100290309 | COMPACT MICROFLUIDIC STRUCTURES FOR MANIPULATING FLUIDS - Disclosed is a method and apparatus for manipulating fluids. The apparatus may include a microfluidic structure including inlet channels ( | 11-18-2010 |
20090232882 | PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER - Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods. | 09-17-2009 |